Armata Pharmaceuticals (ARMP) Retained Earnings (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Retained Earnings of -$616.9 million for Q1 2026, down 318.31% sequentially from $282.6 million in Q4 2025, and down 84.53% YoY from -$4.0 billion in Q1 2025.
Armata Pharmaceuticals (ARMP) Retained Earnings (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Retained Earnings for 14 years, with the latest figure at -$616.9 million in Q1 2026.
- Quarterly Retained Earnings fell 84.53% year-over-year to -$616.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$616.9 million (down 84.53% YoY) and the FY2025 annual result came in at $282.6 million, up 1.15% from the prior year.
- Retained Earnings slipped to -$616.9 million in Q1 2026 per ARMP's latest filing, from $282.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at $282.6 million in Q4 2025 and troughed at -$616.9 million in Q1 2026.
- A 5-year average of -$79.7 million and a median of -$229.5 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 247.31% in 2022, then sank 225.92% in 2025.
- Over 5 years, Retained Earnings stood at -$239.8 million in 2022, then dropped by 28.8% to -$308.8 million in 2023, then surged by 190.46% to $279.4 million in 2024, then climbed by 1.15% to $282.6 million in 2025, then tumbled by 318.31% to -$616.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$616.9 million, $282.6 million, and -$377.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 4.38 Bn |
| 10 | Armata Pharmaceuticals | 181.17 Mn | 157.17 Mn | - | -542.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -542.74 Mn |
| Mar 31, 2026 | -616.88 Mn |
| Dec 31, 2025 | 282.57 Mn |
| Sep 30, 2025 | -377.20 Mn |
| Jun 30, 2025 | -350.56 Mn |
| Mar 31, 2025 | -334.30 Mn |
| Dec 31, 2024 | 279.35 Mn |
| Sep 30, 2024 | -330.34 Mn |
| Jun 30, 2024 | 278.39 Mn |
| Mar 31, 2024 | 276.97 Mn |
| Dec 31, 2023 | -308.82 Mn |
| Sep 30, 2023 | -289.00 Mn |
| Jun 30, 2023 | 276.59 Mn |
| Mar 31, 2023 | 276.35 Mn |
| Dec 31, 2022 | -239.77 Mn |
| Sep 30, 2022 | -229.46 Mn |
| Jun 30, 2022 | -220.85 Mn |
| Mar 31, 2022 | 272.81 Mn |
| Dec 31, 2021 | -202.86 Mn |
| Sep 30, 2021 | 220.32 Mn |